OPK: Transitioning to a therapeutics-focused model with unique multi-specific assets and strong partnerships
The company is shifting from diagnostics to therapeutics, highlighted by ModeX’s multi-specific antibody platform and a robust clinical pipeline. Strategic collaborations with Merck and Regeneron, strong capital position, and active shareholder returns support growth, with several clinical mileston…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.